Augmented the sensitivity of photothermal-ferroptosis therapy in triple-negative breast cancer through mitochondria-targeted nanoreactor
Journal of Controlled Release · 2024-11 · 375 · 733-744
DOI: 10.1016/j.jconrel.2024.09.042 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2024-11. Verfasst von Min Mu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, Department of Radiation Oncology and Department of Head and Neck Onco…. Hauptthemen laut MEDLINE: Mitochondria, Catechin, Ferroptosis, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Major Science and Technology Projects of China, Natural Science Foundation of Sichuan Province.
Abstract (Originalsprache)
Ferroptosis primarily relies on reactive oxygen (ROS) production and lipid peroxide (LPO) accumulation, which opens up new opportunities for tumor therapy. However, a standalone ferroptosis process is insufficient in inhibiting tumor progression. Unlike previously reported Fe-based nanomaterials, we have engineered a novel nanoreactor named IR780/Ce@EGCG/APT, which uses metal-polyphenols network (Ce@EGCG) based on rare-earth cerium and epigallocatechin gallate (EGCG) to encapsulate IR780 and modified with the aptamer (AS1411). The intricately designed nanoreactor is specifically taken up by tumor cells, releasing Ce3+, EGCG, and IR780. On the one hand, Ce3+ triggers ROS production via a Fenton-like reaction, inducing ferroptosis in tumor cells. On the other hand, IR780 accumulates in mitochondria and disrupts mitochondrial function upon laser irradiation, leading to tumor cell apoptosis. EGCG serves as a sensitizer, simultaneously enhancing the sensitivity of tumor cells to ferroptosis and photothermal therapy. After a single dose and three times of 808 nm laser irradiation for treatment, it has been observed that the nanoreactor induces dendritic cells (DCs) maturation, facilitates cytotoxic T lymphocyte infiltration, improves immunosuppressive microenvironment, activates the systemic immune system, and generates long-term immune memory.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, Department of Radiation Oncology and Department of Head and Neck Oncology, West China Hospital, Sichuan University, Chengdu 610041, China.
- National Institute of Measurement and Testing Technology, Chengdu 610021, Sichuan, China.
- Key Laboratory of Xinjiang Phytomedicine Resource and Utilization, Ministry of Education, School of Pharmacy, Shihezi University, Shihezi 832002, China.
- Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, Department of Radiation Oncology and Department of Head and Neck Oncology, West China Hospital, Sichuan University, Chengdu 610041, China.…
Förderung
- National Natural Science Foundation of China
- National Major Science and Technology Projects of China
- Natural Science Foundation of Sichuan Province
Zitieren
APA
Mu, M., Chen, B., Li, H., Fan, R., Yang, Y., Zhou, L., Han, B., Zou, B., Chen, N., & Guo, G. (2024). Augmented the sensitivity of photothermal-ferroptosis therapy in triple-negative breast cancer through mitochondria-targeted nanoreactor. Journal of Controlled Release, 375, 733-744. https://doi.org/10.1016/j.jconrel.2024.09.042
Vancouver
Mu M, Chen B, Li H, Fan R, Yang Y, Zhou L, et al. Augmented the sensitivity of photothermal-ferroptosis therapy in triple-negative breast cancer through mitochondria-targeted nanoreactor. Journal of Controlled Release. 2024;375:733-744. doi:10.1016/j.jconrel.2024.09.042
BibTeX
@article{Mu2024,
author = {Mu, Min and Chen, Bo and Li, Hui and Fan, Rangrang and Yang, Yuanli and Zhou, Lihua and Han, Bo and Zou, Bingwen and Chen, Nianyong and Guo, Gang},
title = {Augmented the sensitivity of photothermal-ferroptosis therapy in triple-negative breast cancer through mitochondria-targeted nanoreactor},
journal = {Journal of Controlled Release},
year = {2024},
volume = {375},
pages = {733--744},
doi = {10.1016/j.jconrel.2024.09.042}
}
EUVIMED